Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ARROWHEAD PHARMACEUTICALS, INC.ARWR · Entity 3472 | Director | August 18, 2026 | August 20, 2026 |
| AVITA Medical, Inc.RCEL · Entity 5905 | Director | November 21, 2022 | November 22, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ARROWHEAD PHARMACEUTICALS, INC.
Report date August 18, 2026 · Filed August 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 111,459 |
Reported balance
After 2026-08-18 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-08-18 · Sale · Disposed 11,600 · Balance 111,459 F1: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $87.20 to $87.44, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F2: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $87.20 to $87.44, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
F2: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions.
AVITA Medical, Inc.
Report date November 21, 2022 · Filed November 22, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 229,543 |
Last balance in matching sequence
After 2022-11-21 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2022-11-21 · Exercise / conversion · Acquired 150,000 · Balance 379,543 F1: The exercise price was converted from A$8.20, which reflects the 100:1 consolidation ratio applied in converting ordinary shares of Predecessor (as defined below) to shares of the Issuer's Common Stock, using the exchange rate as published by the Reserve Bank of Australia in effect on the date of grant (November 30, 2018). F2: Includes 634,602 of the Issuer's CHESS Depositary Interests ("CDIs"). CDIs are units of beneficial ownership in shares of common stock of the Issuer that are publicly traded on the Australian Securities Exchange (the "ASX") and held by CHESS Depositary Nominees Pty, Limited, a subsidiary of ASX Limited, the company that operates the ASX. Five CDIs are equivalent to one share of Common Stock and have all the rights and privileges of Common Stock. The Reporting Person holds 634,602 CDIs, which translate into 126,920 of the shares of Common Stock set forth above. Row 2 · 2022-11-21 · Sale · Disposed 150,000 · Balance 229,543 F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.05 to $7.45. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of the shares of Common Stock sold at each separate price within the ranges set forth in this footnote to this Form 4. F2: Includes 634,602 of the Issuer's CHESS Depositary Interests ("CDIs"). CDIs are units of beneficial ownership in shares of common stock of the Issuer that are publicly traded on the Australian Securities Exchange (the "ASX") and held by CHESS Depositary Nominees Pty, Limited, a subsidiary of ASX Limited, the company that operates the ASX. Five CDIs are equivalent to one share of Common Stock and have all the rights and privileges of Common Stock. The Reporting Person holds 634,602 CDIs, which translate into 126,920 of the shares of Common Stock set forth above. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.99 · Expires 2022-11-27 | Direct | 0 |
Reported balance
After 2022-11-21 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-11-21 · Exercise / conversion · Disposed 150,000 · Balance 0 F4: These Stock Options were originally exercisable for ordinary shares of of AVITA Medical, Ltd., an Australian public company and predecessor to the Issuer ("Predecessor"). Pursuant to a scheme of arrangement, completed on June 30, 2020, the Stock Options became exercisable for shares of Common Stock of the Issuer in the ratio of one share of Common Stock for every 100 ordinary shares of Predecessor for which the Stock Options would otherwise have been exercisable. F1: The exercise price was converted from A$8.20, which reflects the 100:1 consolidation ratio applied in converting ordinary shares of Predecessor (as defined below) to shares of the Issuer's Common Stock, using the exchange rate as published by the Reserve Bank of Australia in effect on the date of grant (November 30, 2018). |
Filing footnotes · ownership attribution and instrument terms
F1: The exercise price was converted from A$8.20, which reflects the 100:1 consolidation ratio applied in converting ordinary shares of Predecessor (as defined below) to shares of the Issuer's Common Stock, using the exchange rate as published by the Reserve Bank of Australia in effect on the date of grant (November 30, 2018).
F2: Includes 634,602 of the Issuer's CHESS Depositary Interests ("CDIs"). CDIs are units of beneficial ownership in shares of common stock of the Issuer that are publicly traded on the Australian Securities Exchange (the "ASX") and held by CHESS Depositary Nominees Pty, Limited, a subsidiary of ASX Limited, the company that operates the ASX. Five CDIs are equivalent to one share of Common Stock and have all the rights and privileges of Common Stock. The Reporting Person holds 634,602 CDIs, which translate into 126,920 of the shares of Common Stock set forth above.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.05 to $7.45. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of the shares of Common Stock sold at each separate price within the ranges set forth in this footnote to this Form 4.
F4: These Stock Options were originally exercisable for ordinary shares of of AVITA Medical, Ltd., an Australian public company and predecessor to the Issuer ("Predecessor"). Pursuant to a scheme of arrangement, completed on June 30, 2020, the Stock Options became exercisable for shares of Common Stock of the Issuer in the ratio of one share of Common Stock for every 100 ordinary shares of Predecessor for which the Stock Options would otherwise have been exercisable.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Armata Pharmaceuticals, Inc.
Report date December 31, 2019 · Filed February 14, 2020
Section 16 reporting ended · disclosed 2020-02-14. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Warrant to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.32 · Expires 2021-11-22 | IndirectSee Footnote | 0 |
Reported balance
After 2019-05-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-05-09 · Other · Disposed 46,666 · Balance 0 F4: Price reported is reflective of adjustments made to the exercise price after the date of issuance pursuant to the terms of the warrant. F1: The reported securities were redeemed by the issuer for $12,065.46. F2: The number of shares of common stock for which the warrant was exercisable does not reflect the 1-for-14 reverse stock split that was effected on May 9, 2019. F3: The warrant was held by One Funds Management Limited as Trustee for Asia Pacific Healthcare Fund II ("One Funds Management"). The Reporting Person may be deemed to have shared voting and dispositive power over the shares beneficially owned by One Funds Management but disclaims such beneficial ownership, except to the extent of his pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities were redeemed by the issuer for $12,065.46.
F2: The number of shares of common stock for which the warrant was exercisable does not reflect the 1-for-14 reverse stock split that was effected on May 9, 2019.
F3: The warrant was held by One Funds Management Limited as Trustee for Asia Pacific Healthcare Fund II ("One Funds Management"). The Reporting Person may be deemed to have shared voting and dispositive power over the shares beneficially owned by One Funds Management but disclaims such beneficial ownership, except to the extent of his pecuniary interest therein, if any.
F4: Price reported is reflective of adjustments made to the exercise price after the date of issuance pursuant to the terms of the warrant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 14, 2020 Filed May 18, 2020 22:27 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | Exercise / conversionCommon Stock | 5,000 | $2.01 | $10,050.00 |
DisclosureSEC source: 0001209191-20-030214 · doc4.xml · nonDerivative · entry 2 PERRY MICHAEL S · CIK 0001250379 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 14, 2020 Filed May 18, 2020 22:27 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | Exercise / conversionCommon Stock | 7,000 | $4.75 | $33,250.00 |
DisclosureSEC source: 0001209191-20-030214 · doc4.xml · nonDerivative · entry 1 PERRY MICHAEL S · CIK 0001250379 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 12, 2020 Filed May 13, 2020 22:48 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 6,100 | $36.42 | $222,162.00 |
DisclosureSEC source: 0001209191-20-028978 · doc4.xml · nonDerivative · entry 2 PERRY MICHAEL S · CIK 0001250379 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Read SEC document |
| May 12, 2020 Filed May 13, 2020 22:48 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 29,900 | $35.71 | $1,067,729.00 |
DisclosureSEC source: 0001209191-20-028978 · doc4.xml · nonDerivative · entry 1 PERRY MICHAEL S · CIK 0001250379 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,100 F1 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.35 to $36.35, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| January 01, 2020 Filed Jan 3, 2020 23:08 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GrantCommon Stock | 8,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-001366 · doc4.xml · nonDerivative · entry 1 PERRY MICHAEL S · CIK 0001250379 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,000 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date. Read SEC document |
| September 11, 2019 Filed Sep 12, 2019 00:09 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 85,000 | $30.00 | $2,550,000.00 |
DisclosureSEC source: 0001209191-19-049237 · doc4.xml · nonDerivative · entry 2 PERRY MICHAEL S · CIK 0001250379 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,000 Read SEC document |
| September 09, 2019 Filed Sep 12, 2019 00:09 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 100,000 | $28.90 | $2,890,000.00 |
DisclosureSEC source: 0001209191-19-049237 · doc4.xml · nonDerivative · entry 1 PERRY MICHAEL S · CIK 0001250379 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,000 F1 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.88 to $28.95, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| May 22, 2019 Filed May 25, 2019 01:30 UTC | Armata Pharmaceuticals, Inc. ARMP · Entity 6329 | GrantStock Option (Right to Buy) · Derivative | 27,383 | $0.00 Strike: $3.15 | $0.00 |
DisclosureSEC source: 0001144204-19-028256 · tv522362_4.xml · derivative · entry 1 PERRY MICHAEL S · CIK 0001250379 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,383 Underlying: Common Stock · 27,383 shares Expires 2029-05-22 F1 · derivative.exercise_date: The stock option vests as to fifty percent (50%) of the underlying shares of common stock on each annual anniversary of the date of grant. Read SEC document |
| May 09, 2019 Filed Feb 14, 2020 22:58 UTC | Armata Pharmaceuticals, Inc. ARMP · Entity 6329 | OtherWarrant to Purchase Common Stock · Derivative | 46,666 | $12,065.46 Strike: $0.32 | $563,046,756.36 |
DisclosureSEC source: 0001104659-20-022091 · tm208184-6_form5.xml · derivative · entry 1 PERRY MICHAEL S · CIK 0001250379 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 46,666 shares Expires 2021-11-22 F4 · derivative.exercise_price: Price reported is reflective of adjustments made to the exercise price after the date of issuance pursuant to the terms of the warrant. F1 · kind: The reported securities were redeemed by the issuer for $12,065.46. F2 · derivative.underlying_shares: The number of shares of common stock for which the warrant was exercisable does not reflect the 1-for-14 reverse stock split that was effected on May 9, 2019. F3 · ownership.nature: The warrant was held by One Funds Management Limited as Trustee for Asia Pacific Healthcare Fund II ("One Funds Management"). The Reporting Person may be deemed to have shared voting and dispositive power over the shares beneficially owned by One Funds Management but disclaims such beneficial ownership, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| January 01, 2019 Filed Jan 4, 2019 01:15 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GrantCommon Stock | 36,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-001543 · doc4.xml · nonDerivative · entry 1 PERRY MICHAEL S · CIK 0001250379 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221,000 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date. Read SEC document |
| March 22, 2018 Filed Mar 27, 2018 00:51 UTC | Armata Pharmaceuticals, Inc. APHB · Entity 6329 | PurchaseCommon Stock | 181,820 | $1.10 | $200,002.00 |
DisclosureSEC source: 0001209191-18-021679 · doc4.xml · nonDerivative · entry 3 PERRY MICHAEL S · CIK 0001250379 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 411,105 F3 · ownership.nature: The shares are held by One Funds Management. The Reporting Person may be deemed to have shared voting and dispositive power over the shares beneficially owned by One Funds Management but disclaims such beneficial ownership, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| January 01, 2018 Filed Jan 4, 2018 00:42 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-001536 · doc4.xml · nonDerivative · entry 1 PERRY MICHAEL S · CIK 0001250379 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,000 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date. Read SEC document |
| September 19, 2017 Filed Mar 27, 2018 00:51 UTC | Armata Pharmaceuticals, Inc. APHB · Entity 6329 | PurchaseCommon Stock | 105,015 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-021679 · doc4.xml · nonDerivative · entry 2 PERRY MICHAEL S · CIK 0001250379 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 229,285 F1 · price: The Shares were issued pursuant to a Common Stock Issuance Agreement, dated April 8, 2016, between the Issuer and certain holders of the Issuer's Series B Preferred Stock (the "Holders"), as amended. As consideration for the Shares, among other things, the Holders waived their right to receive certain cash payments to which they were entitled upon the conversion of their Series B Preferred Stock and also waived certain registration rights relating to certain future registration statements or public offerings that may be filed or conducted by the Issuer. F3 · ownership.nature: The shares are held by One Funds Management. The Reporting Person may be deemed to have shared voting and dispositive power over the shares beneficially owned by One Funds Management but disclaims such beneficial ownership, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| September 07, 2017 Filed Sep 12, 2017 21:56 UTC | Armata Pharmaceuticals, Inc. APHB · Entity 6329 | GrantStock Option (Right to Buy) · Derivative | 10,900 | $0.00 Strike: $0.91 | $0.00 |
DisclosureSEC source: 0001209191-17-052468 · doc4.xml · derivative · entry 1 PERRY MICHAEL S · CIK 0001250379 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,900 Underlying: Common Stock · 10,900 shares Expires 2027-09-06 Read SEC document |
| June 29, 2017 Filed Mar 27, 2018 00:51 UTC | Armata Pharmaceuticals, Inc. APHB · Entity 6329 | PurchaseCommon Stock | 5,757 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-021679 · doc4.xml · nonDerivative · entry 1 PERRY MICHAEL S · CIK 0001250379 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 124,270 F1 · price: The Shares were issued pursuant to a Common Stock Issuance Agreement, dated April 8, 2016, between the Issuer and certain holders of the Issuer's Series B Preferred Stock (the "Holders"), as amended. As consideration for the Shares, among other things, the Holders waived their right to receive certain cash payments to which they were entitled upon the conversion of their Series B Preferred Stock and also waived certain registration rights relating to certain future registration statements or public offerings that may be filed or conducted by the Issuer. F2 · balance_after: The reporting person acquired beneficial ownership of these shares upon his appointment as a Managing Director of Bioscience Managers Pty Ltd. in April 2017. Bioscience Managers Pty Ltd. is an affiliate of One Funds Management Limited as Trustee for Asia Pacific Healthcare Fund II ("One Funds Management"). F3 · ownership.nature: The shares are held by One Funds Management. The Reporting Person may be deemed to have shared voting and dispositive power over the shares beneficially owned by One Funds Management but disclaims such beneficial ownership, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| January 01, 2017 Filed Jan 5, 2017 01:52 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GrantCommon Stock | 80,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-001622 · doc4.xml · nonDerivative · entry 1 PERRY MICHAEL S · CIK 0001250379 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,000 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.